Laboratory cross-comparison of tumor BRCA1/2 analysis in a multicenter epithelial ovarian cancer series: The BORNEO GEICO60-0 study.
Ignacio Romero(Valencian Infertility Institute), Ana Vivancos(Vall d'Hebron Institute of Oncology), Alfonso Yubero(Marqués de Valdecilla University Hospital), Alejandro Gallego(Hospital Universitario La Paz), Ana B. Sánchez(Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana), Lorena Fariñas-Madrid(Vall d'Hebron Hospital Universitari), Jesús Alarcón(Hospital Universitario Son Espases), Ana Oaknin(Hebron University), Juan Cueva(Instituto de Investigación Sanitaria de Santiago), José Antonio López‐Guerrero(Consejo Superior de Investigaciones Científicas), Andrés Poveda(Hospital Quirónsalud Barcelona), Isabel Palacio Vázquez(Hospital Universitario Central de Asturias), Cristina Segura, Raúl Márquez(MD Anderson Cancer Center Madrid), Zaida García‐Casado(Fundación Instituto Valenciano de Oncología), Maria Pilar Barretina-Ginesta(Universitat de Girona), Judit Matito(Oryzon Genomics (Spain))
Cited by 0
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k